Novel antithrombotic agents and the risk of bleeding

Area of Science:

• Cardiovascular Surgery
• Anesthesiology
• Hematology

Background:

• Coronary patients often require bypass surgery while on antiplatelet (PLT) therapy.
• Discontinuing anti-PLT treatment may not be feasible or advisable before surgery.
• Managing perioperative bleeding in these patients is critical.

Purpose of the Study:

• To evaluate the efficacy of intraoperative aprotinin in reducing bleeding and transfusion requirements.
• To identify strategies for managing persistent bleeding in patients undergoing bypass surgery on antiplatelet drugs.

Main Methods:

• Review of clinical data on patients undergoing coronary artery bypass grafting.
• Analysis of the impact of intraoperative aprotinin administration.
• Assessment of the role of Factor VIIa in cases of persistent bleeding.

Main Results:

• Intraoperative aprotinin significantly reduces postoperative bleeding.
• Aprotinin administration leads to decreased transfusion requirements.
• Factor VIIa is considered for persistent surgical bleeding.

Conclusions:

• Intraoperative aprotinin is beneficial for managing bleeding in coronary patients on antiplatelet therapy undergoing bypass surgery.
• Factor VIIa serves as a potential treatment for refractory intraoperative bleeding.